The other biomarkers, such as sST2, hs-TnT, galectin-3 and hs-CRP, have predicted all-cause and cardiac mortality among patients with heart failure, stable CAD and even in general population[6,8,10,20,21], but only one of these studies focused specifically on the occurrence of SCD in patients with CHF [11] while none focused on the occurrence of SCD in patients with preserved left ventricular function. The gene discussed is LGALS3; the disease is heart failure.